-
公开(公告)号:EP4424371A2
公开(公告)日:2024-09-04
申请号:EP24173326.0
申请日:2016-02-29
IPC分类号: A61P31/14
CPC分类号: A61K31/4453 , C07D401/14 , C07D215/22 , C07D233/94 , C07D405/12 , C07H15/252 , C07H17/08 , C07H19/06 , C07C229/36 , C07D249/08 , C07D457/04 , C07D457/06 , C07D473/18 , C07D473/30 , C07D261/16 , C07D265/18 , C07D491/22 , C07D499/00 , C07D277/56 , C07D209/14 , C07D499/24 , C07D209/24 , C07D501/22 , C07C255/41 , C07D519/00 , C07D519/02 , C07K7/08 , C07D285/28 , C07D211/22 , C07D307/52 , A61P31/00 , C07C69/157 , C07C57/30 , C07C59/105 , C07B2200/1320130101 , C07C211/38 , C07C215/58 , C07C2603/7420170501 , C07J5/0053 , A61K31/704 , A61K31/13 , A61K31/137 , A61K31/192 , A61K31/198 , A61K31/277 , A61K31/4045 , A61K31/4164 , A61K31/4196 , A61K31/426 , A61K31/43 , A61K31/445 , A61K31/4745 , A61K31/48 , A61K31/496 , A61K31/4985 , A61K31/506 , A61K31/522 , A61K31/536 , A61K31/545 , A61K31/546 , A61K31/549 , A61K31/573 , A61K31/635 , A61K31/7048 , A61K31/7072 , A61K38/12 , A61K31/34 , A61K31/431 , A61K31/4709 , A61K31/603 , Y02A50/30
摘要: A platform drug delivery system and a method of improving the delivery of low solubility pharmaceuticals utilizing crystal engineering and Theanine dissolution resulting in enhanced bioactivity, dissolution rate, and solid state stability.